Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective

叶酸 奥沙利铂 内科学 养生 肿瘤科 癌症 指南 结直肠癌 医学 胃肠病学 病理
作者
Hanneke W.M. van Laarhoven,Sarah Derks
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10389): 1630-1631 被引量:9
标识
DOI:10.1016/s0140-6736(23)00732-8
摘要

Advances in biomarker-based targeted treatments have been slow for patients with stage IV gastro-oesophageal adenocarcinoma, with median overall survival for patients with human epidermal growth factor receptor 2 (HER2)-negative disease not exceeding a year. 1 Ter Veer E Haj Mohammad N van Valkenhoef G et al. The efficacy and safety of first-line chemotherapy in advanced esophagogastric cancer: a network meta-analysis. J Natl Cancer Inst. 2016; 108djw166 Crossref PubMed Scopus (84) Google Scholar Studies on the efficacy of combining chemotherapy with programmed death 1 (PD-1) inhibitors have changed the standard of care for these patients. 2 Lordick F Carneiro F Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33: 1005-1020 Summary Full Text Full Text PDF PubMed Scopus (112) Google Scholar In The Lancet, Kohei Shitara and colleagues 3 Shitara K Lordick F Bang Y-J et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023; (published online April 14.)https://doi.org/10.1016/S0140-6736(23)00620-7 Summary Full Text Full Text PDF PubMed Scopus (15) Google Scholar report the results of the phase 3 SPOTLIGHT trial, which investigated the effect of claudin-18 isoform 2 (CLDN18.2) targeting, using the monoclonal antibody zolbetuximab plus mFOLFOX6 (modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen) in patients from 215 centres in 20 countries with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. CLDN18.2 is a tight junction protein that is specifically expressed in around 40% of HER2-negative adenocarcinomas of the upper gastrointestinal tract and has little expression elsewhere in the body, making it an attractive therapeutic target. 283 patients (median age 62·0 years, IQR 51·0–69·0; 176 [62%] men and 107 [38%] women; 88 [31%] from Asia and 195 [69%] from non-Asian regions) were randomly assigned to zolbetuximab (800 mg/m2 loading dose followed by 600 mg/m2 every 3 weeks) plus mFOLFOX6 (every 2 weeks). 282 patients (median age 60·0 years, 50·0–69·0; 175 (62%) men and 107 [38%] women; 89 [32%] from Asia and 193 [68%] from non-Asian regions) were randomly assigned to placebo. The primary endpoint was progression-free survival by independent review committee in all randomly assigned patients. The median progression-free survival was 10·61 months (95% CI 8·90–12·48) in the zolbetuximab group versus 8·67 months (8·21–10·28) in the placebo group (hazard ratio [HR] 0·75, 95% CI 0·60–0·94; p=0·0066). The median overall survival was 18·23 months (95% CI 16·43–22·90) in the zolbetuximab group versus 15·54 months (13·47–16·53) in the placebo group (HR 0·75, 95% CI 0·60–0·93; p=0·0053). Treatment-emergent grade 3 or worse adverse events occurred in 242 (87%) of 279 patients in the zolbetuximab group versus 216 (78%) of 278 patients in the placebo group. Treatment-related deaths occurred in five (2%) patients in the zolbetuximab group versus four (1%) patients in the placebo group. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialTargeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6 might represent a new first-line treatment in these patients. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
heavenzzz发布了新的文献求助10
1秒前
所所应助大反应釜采纳,获得10
1秒前
Orange应助吴所谓采纳,获得50
2秒前
2秒前
无知小白完成签到,获得积分10
2秒前
moumou完成签到,获得积分10
3秒前
李钧鹏完成签到,获得积分10
3秒前
laber应助小诗人采纳,获得50
4秒前
有魅力的不评完成签到,获得积分10
4秒前
麋鹿发布了新的文献求助10
4秒前
6秒前
火星上含海完成签到,获得积分10
8秒前
小马甲应助张雯思采纳,获得10
12秒前
41应助张雯思采纳,获得10
12秒前
李健的粉丝团团长应助123采纳,获得10
12秒前
孙燕应助张雯思采纳,获得10
12秒前
打打应助张雯思采纳,获得10
12秒前
情怀应助张雯思采纳,获得10
12秒前
孙燕应助张雯思采纳,获得10
12秒前
Hello应助张雯思采纳,获得10
12秒前
搜集达人应助张雯思采纳,获得10
12秒前
赘婿应助张雯思采纳,获得10
12秒前
今后应助张雯思采纳,获得10
12秒前
量子星尘发布了新的文献求助10
13秒前
麋鹿完成签到,获得积分20
13秒前
赵子完成签到,获得积分10
16秒前
英姑应助会飞的鱼采纳,获得10
17秒前
20秒前
FashionBoy应助勤恳化蛹采纳,获得10
21秒前
23秒前
平淡小白菜完成签到,获得积分10
25秒前
lzx发布了新的文献求助10
26秒前
Jun发布了新的文献求助10
26秒前
隐形曼青应助搞怪的紫易采纳,获得10
27秒前
28秒前
xxddw发布了新的文献求助10
29秒前
大反应釜发布了新的文献求助20
33秒前
123发布了新的文献求助10
33秒前
hugeyoung完成签到,获得积分10
36秒前
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174